

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Carestio Daniel A</u> (Last) (First) (Middle) <u>C/O 5960 HEISLEY ROAD</u> (Street) <u>MENTOR OH 44060</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>08/27/2015</u>	3. Issuer Name and Ticker or Trading Symbol <u>STERIS CORP [STE]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Sr. V. P., Isomedix & Life Sci</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Shares, No Par Value</u>	<u>23,951⁽¹⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
<u>Option to Purchase Common Shares</u>	<u>(2)</u>	<u>05/30/2022</u>	<u>Common Shares, No Par Value</u> 2,225	<u>29.94</u>	<u>D</u>	
<u>Option to Purchase Common Shares</u>	<u>(3)</u>	<u>05/31/2023</u>	<u>Common Shares, No Par Value</u> 10,120	<u>45.34</u>	<u>D</u>	
<u>Option to Purchase Common Shares</u>	<u>(4)</u>	<u>05/30/2024</u>	<u>Common Shares, No Par Value</u> 7,000	<u>53.52</u>	<u>D</u>	
<u>Option to Purchase Common Shares</u>	<u>(5)</u>	<u>08/10/2025</u>	<u>Common Shares, No Par Value</u> 8,000	<u>67.98</u>	<u>D</u>	

Explanation of Responses:

- 16,800 of these Common Shares are restricted. The restrictions on these Common Shares lapse as follows: 4,500 on May 31, 2016; 3,300 on May 31, 2017; 4,000 on May 30, 2018; and 5,000 on May 28, 2019.
- These will become exercisable as follows: 2,225 on May 30, 2016.
- These options became or will become exercisable as follows: 2,530 on May 31, 2014; 2,530 on May 31, 2015; 2,530 on May 31, 2016 and 2,530 on May 31, 2017.
- These options became or will become exercisable as follows: 1,750 on May 30, 2015; 1,750 on May 30, 2016; 1,750 on May 30, 2017 and 1,750 on May 30, 2018.
- These options become exercisable as follows: 2,000 on May 28, 2016; 2,000 on May 28, 2017; 2,000 on May 28, 2018 and 2,000 on May 28, 2019.

Remarks:

/s/ Julia Kipnis, Authorized Representative under Power of Attorney 09/02/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

